Recently, Vivoryon Therapeutics presented new analysis data for varoglutamstat at the 2024 American Society of Nephrology (ASN) meeting.

Xencor has administered the initial dose to a participant in the Phase 1/2 trial of XmAb®942, aimed at treating inflammatory bowel disease.

Givosiran Sodium, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

HiFiBiO Therapeutics has gained FDA approval for its IND application concerning HFB200604, a leading BTLA agonist antibody.

Casdatifan is a small molecule drug designed to target HIF-2α, and it is being developed for the treatment of neoplasms, urogenital diseases, and digestive system disorders.

Sutro Biopharma has launched the REFRαME-P1 Trial to support registration of Luvelta for children with CBF/GLIS AML.

Novartis will acquire a clinical-stage molecular glue named MRT-6160, providing Monte Rosa with an upfront payment of $150 million.

UCB presented Phase 2a findings from the TOGETHER (AH0003) trial, which explored the safety, effectiveness, and tolerability of bepranemab.

Patisiran sodium, a pioneering therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

AiCuris begins a Phase 1 trial for the antiviral drug AIC468 targeting BK virus infections in kidney transplant patients.

Bexagliflozin is a small molecule drug designed to target SGLT2 and is primarily used in the therapeutic areas of endocrinology and metabolic disease.

JCR Pharmaceuticals has begun the initial dosing for the Phase I clinical trial of JR-441 targeting Mucopolysaccharidosis Type IIIA.